Welcome to our dedicated page for Concord Medical news (Ticker: CCM), a resource for investors and traders seeking the latest updates and insights on Concord Medical stock.
Concord Medical Services Holdings Limited (NYSE: CCM) is a China-based healthcare provider focused on oncology. Its public announcements describe a full cycle of premium oncology services, including cancer diagnosis, treatment, education and prevention, delivered through self-owned cancer hospitals and clinics and a network of partnered hospitals across China. The company’s news flow provides insight into how it develops and operates these oncology services.
News about Concord Medical frequently covers its progress in proton therapy and precision radiation therapy. Recent releases highlight Guangzhou Concord Cancer Hospital’s commencement of proton therapy operations, specialized treatment protocols for conditions such as nasopharyngeal carcinoma and central nervous system tumors, and pediatric oncology cases. Another subsidiary announcement reports completion of what it describes as China’s first proton therapy for choroidal malignant melanoma at Guangzhou Concord Cancer Center, using pencil beam scanning proton therapy with real-time guidance.
Investors and observers can also find updates on regulatory and licensing milestones, such as the granting of a large medical equipment procurement license for proton equipment and the approval of a Registration Certificate for Medical Device for proton therapy equipment related to the company’s operations. These items help explain the timing and scope of Concord Medical’s proton therapy services.
In addition, Concord Medical’s news includes interim financial results, details of its annual and special shareholder meetings, changes in governance, and developments at its listed subsidiary Concord Healthcare Group Co., Ltd. on the Hong Kong Stock Exchange. For users following CCM, this news page brings together earnings releases, clinical and technology updates, regulatory announcements and corporate actions that shape the company’s oncology-focused business over time.
Concord Medical Services Holdings Limited (NYSE: CCM) announced key management changes effective September 30, 2022. Chief Financial Officer and President Yaw Kong Yap stepped down upon reaching retirement age, with Boxun Zhang appointed as his successor. Independent directors Boxun Zhang and Weibo Yin resigned for personal reasons. New independent directors Wayne Yu and Hongzhong Liu joined the Board, enhancing its expertise. The company expresses gratitude to outgoing management and directors, emphasizing the aim to continue delivering value to shareholders through its oncology services across China.
Concord Medical Services Holdings Limited (NYSE: CCM) reported a significant financial downturn for the first half of 2022, with total net revenues of RMB144.3 million (US$21.5 million), a 25.2% decline from RMB192.9 million in the same period in 2021. The company's gross loss surged to RMB88.7 million (US$13.2 million), compared to a gross profit of RMB2.4 million last year, reflecting a gross loss margin of 61.5%. Net loss attributable to shareholders rose to RMB114.7 million (US$17.1 million). Although revenues from its hospital business increased by 29.2%, the network business plummeted by 52.3% due to COVID-19 disruptions.
Concord Medical Services Holdings Limited (NYSE: CCM) announced that its subsidiary, Concord Healthcare Group, filed an application on May 31, 2022, for a minority stake listing on The Stock Exchange of Hong Kong Limited. The announcement highlights Concord Healthcare as a leading oncology-focused platform in China, offering comprehensive cancer care services. However, completion of the listing is uncertain and subject to the HKSE's approval and market conditions. The Company emphasizes that this announcement does not constitute an offer to sell securities in any jurisdiction.
Concord Medical Services Holdings Limited (NYSE: CCM) announced the filing of its annual report on Form 20-F for the fiscal year ending December 31, 2021, with the U.S. Securities and Exchange Commission. The annual report is available electronically on Concord Medical's investor relations website and the SEC's website. The company is dedicated to providing premium oncology services, including diagnosis, treatment, and prevention through its network of cancer hospitals in China, emphasizing technological advancements like the proton therapy system.
Concord Medical Services Holdings Limited (NYSE: CCM) reported strong financial results for the first half of 2021, with total net revenues reaching RMB192.9 million ($29.9 million), a 132.4% increase from RMB83.0 million in the same period last year. The revenue split included RMB128.7 million from the network business and RMB64.2 million from hospitals. Gross profit improved to RMB2.4 million, recovering from a loss of RMB3.5 million in 2020. However, the net loss attributable to shareholders decreased to RMB90.3 million from RMB128.8 million. The company opened a new hospital and internet hospital, enhancing its service offerings.
Concord Medical Services Holdings Limited (NYSE: CCM) announced its 2021 annual general meeting of shareholders will take place on December 29, 2021, in Beijing. The meeting is for discussing company affairs with management, with no proposals for shareholder approval. The shareholder record date is November 29, 2021. The company's audited financial statements for the year ending December 31, 2020, are available on their investor relations website. Concord Medical specializes in cancer treatment and operates numerous advanced cancer hospitals and diagnostic centers across China.
Concord Medical Services Holdings Limited (NYSE: CCM) announced that its Guangzhou Concord Cancer Center (GCCC) has become a designated medical institution for Social Healthcare Insurance, enhancing patient access to healthcare. The National Healthcare Security Administration supports this system, covering over 95% of China's population. In Guangzhou, it can pay up to 90% of medical services. GCCC also partnered with various insurance companies, ensuring extensive coverage for patients. Operating since 2010, GCCC provides comprehensive cancer services from prevention to recovery, supported by Meizhong Jiahe Medical Science & Technology Development Group.
Concord Medical Services Holdings Limited (NYSE: CCM) announced two projects shortlisted for the '5G+Healthcare' pilot project by China's Ministry of Industry and Information Technology. The projects include the Jiahe Cloud Imaging Remote Medical Information Diagnosis Platform, which offers solutions for remote diagnosis, and the Jiahe Feiyun Intelligent Radiotherapy Cloud Service Platform, providing comprehensive radiotherapy management services. This recognition highlights Concord's commitment to advancing cancer care in China through technology.
Concord Medical Services Holdings Limited (NYSE: CCM) filed its annual report on Form 20-F for the fiscal year ending December 31, 2020. The report is accessible on the Company's investor relations and SEC websites. Concord Medical specializes in cancer treatment and operates an extensive network of cancer hospitals and diagnostic centers across China. Additionally, the Company has established proton therapy facilities and focuses on advanced cancer care and medical equipment services. Shareholders can request a hard copy of the report free of charge.
Concord Medical Services Holdings Limited (NYSE: CCM) announced that its subsidiary, Shanghai Concord Cancer Center, has entered an agreement to purchase the Proteus Plus proton therapy system from CGN Medical Technology. Located in Shanghai, the center is under construction since September 2017 and aims to be a leading facility for cancer treatment, covering 70 acres with over 400 beds. The hospital will offer a multidisciplinary approach to cancer care and leverage advanced international technologies.
FAQ
What is the current stock price of Concord Medical (CCM)?
What is the market cap of Concord Medical (CCM)?
